注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Infinity Pharmaceuticals Inc是一家专注于为癌症患者开发药物的临床阶段的生物制药公司。该公司专注于推进eganelisib,也称为IPI-549,这是一种口服、临床阶段的免疫肿瘤候选产品,通过选择性抑制磷酸肌醇-3-激酶-γ(PI3K-γ)酶对巨噬细胞进行重新编程。其eganelisib临床开发项目包括免疫肿瘤学-3(MARIO-3)、MARIO-275和MARIO-1中的巨噬细胞重编程。MARIO-3是一项多臂II期研究,旨在评估eganelisib在转移性三阴性乳腺癌(TNBC)和肾细胞癌(RCC)一线治疗中的作用。MARIO-275是其全球、随机、安慰剂对照的II期研究,旨在评估在nivolumab(也称为Opdivo)中加入eganelisib对未经检查的晚期尿路上皮癌(UC)的疗效。MARIO-1正在进行1/1b期临床研究。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Anthony B. Evnin | 82 | 2006 | Independent Director |
Dmitry I. Gabrilovich | - | 2018 | Member of Scientific Advisory Board |
David William Beier | 74 | 2018 | Independent Director |
Norman C. Selby | 71 | 2012 | Lead Independent Director |
F. Stephen Hodi | - | 2018 | Member of Scientific Advisory Board |
Jeffery L. Kutok | 56 | 2017 | Chairman of Scientific Advisory Board |
Samuel Agresta | 50 | 2018 | Chair of Clinical Advisory Board |
David H. Munn | - | 2018 | Member of Scientific Advisory Board |
Roy Steven Herbst | 60 | 2018 | Member of Scientific Advisory Board |
Padmanee Sharma | - | - | Member of Clinical Advisory Board |
Michael Postow | - | - | Member of Clinical Advisory Board |
Toni K. Choueiri | - | - | Member of Clinical Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核